Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Abstract

The current study demonstrated favorable 5- and 7-year PRS rates for platinum-sensitive REOC patients undergoing SCS + HIPEC, which encourages the inclusion of patients in randomized clinical trials for definitive conclusions to be drawn.

Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer

“…The HIPEC group experienced longer secondary responses, and 53% of those patients experienced a longer clinical remission after their recurrence than after their initial treatment. In 2015, this group published their 5- and 7-year survival outcomes for 70 women who were treated with SCS and cisplatin- or oxaliplatin-based HIPEC for recurrent disease [36]. Their findings were consistent with the 2012 report, with greater than 52% of patients experiencing a longer second clinical remission than their first.…”

What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature

“…Studies not reporting on long-term survival after ovarian cancer recurrence and studies reporting on women with borderline ovarian tumors or germ cell tumors of the ovary were excluded. After cross-searching the references of the 9 studies identified using this strategy, 8 additional studies were identified (17)(18)(19)(20)(21)(22)(23)(24). In summary, 17 studies were included in this review.…”

“…Optimal surgical cytoreduction at the time of recurrence with no residual tumor left behind was described as a reliable predictor of post-recurrence LTSROC in four studies (7,10,12,18). For example, in a series of 87 women with recurrence after early-stage ovarian cancer, Gadducci et al identified two independent predictors of post recurrence survival, i.e.…”

Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

“…High-dose chemotherapy can be used because the plasma-peritoneal barrier results in little absorption into the blood stream [13,14]. In addition, there is higher peritoneal penetration in comparison to IV regimen, and HIPEC does not have the limitation of traditional IP regimen of post-operative adhesions [15,16]. Hyperthermia itself has cytotoxic effects and can increase the depth of tumor penetration by the chemotherapeutic agent up to 3 mm and moreover can potentiate its antineoplastic effects [17][18][19][20].…”